Thread by @stockekonomics

#laurus labs business updates of last one year
Why #LAURUS is rising
Laurus has three segments
1.Generic Api
2.Generic FDF
3.Custom synthesis and ingredients
Generic Api almost 55% of business
First line products-Lamivudine, Dolutegravir

Second line products-Lopinavir Ritonavir Darunavir
Dolutegravir launched in q4 fy20
Second line APIs will be launched in second half of this financial year
Generic FDF
Forms almost 36% of business
Received approval for TLE 400 and TLE600

Europe- entered into long term partnership with a EU region for 1 billion units supply
TLE 400 launch in Q2 FY21 limited competition drug
Total market size
1.5 billion dollars
Dolutegravir based is 1 billion dollars
TLE based is 500 million dollars

.CDMO business
Have 47 active projects
started commercial supplies for 4 projects
CDMO business growing at 40% CAGR since last 5 years

Current capacity
3407 KL reactor capacity
5 billion units for FDF
Dedicated unit for custom synthesis
.Current expansion
Internal efficiency solutions to give some capacity to meet short term demands in formulations

API capacity to be increased by 20% in next 9 moths
Formulation capacity to be increased to 9 billion units in next 12-15 months
Fourth segment of Laurus
Acquisition of Laurus bio with 18000 litres capacity

API capacities increasing by almost 20% to 5500 Kl in next 12 months. 1 block inaugurated in January. One is coming in March one in May.
Formulation debottlenecking capacity of 1 billion units to be available for commercial manufacturing by end of Q4

Formulations brownfield expansion to be operational in a phased manner from August 2021 and Fully operational by FY2022 end
Laurus bio fermentation capacityof 180000 litres to be completed by march end or April starting
Source - q2 Q3 2020 and q1 2020 concalls and presentation